Pfizer's Sutent Expanded Indication: 'Hope' Or 'False Hope'?

 
• By Derrick Gingery

US FDA Oncologic Drugs Advisory Committee casts tie vote on proposed expansion of Sutent's renal cell carcinoma indication, mirroring debate FDA having internally.

FDA Advisory Committee Feature image
Oncologic Drugs Advisory Committee votes 6-6 on whether the risk-benefit profile for Sutent's indication expansion is acceptable.

More from US FDA Performance Tracker

More from Regulatory Trackers